G3R777 (G3R777_GORGO) Gorilla gorilla gorilla (Western lowland gorilla)
Stratifin UniProtKBInterProSTRINGInteractive Modelling
248 aa; Sequence (Fasta) ;
5 identical sequences: Homo sapiens: P31947; Pan troglodytes: H2RC87, A0A6D2X694; Pan paniscus: A0A2R8ZKA8; Nomascus leucogenys: G1SAD1
It is possible new templates exist for this target since these models were created.
Available Structures
449 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| Crystal Structure of human 14-3-3 sigma in Complex with Raf1 peptide (6mer) |
Heteromer P04049; P31947; | 100 | 2×CL; 6×MG; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1014 |
Heteromer P31947; Q13526; | 100.0 | 2×SFW; 4×CA; 2×CL; | |||
| Co-soaked stabilizers for ERa - 14-3-3 interaction (884_AZ354) |
Heteromer P03372; P31947; | 99.13 | 6×MG; 2×GEH; 2×LF5; | |||
| Co-soaked stabilizers for ERa - 14-3-3 interaction (844_AZ210) |
Heteromer P03372; P31947; | 99.13 | 6×MG; 2×SSX; 2×GEH; | |||
| co-soaked stabilizers for ERa - 14-3-3 interaction (884_AZ244) |
Heteromer P03372; P31947; | 99.13 | 6×MG; 2×GEH; 2×SG0; | |||
| Cys-42-tethered stabilizer 12 of 14-3-3(sigma)/ERa PPI |
Heteromer P03372; P31947; | 99.13 | 6×MG; 2×T5Z; | |||
| 14-3-3 sigma sirtuin-3 phospho-peptide complex |
Heteromer P31947; Q9NTG7; | 100 | 6×MG; 4×CA; 2×CL; | |||
| 14-3-3 sigma in complex with IkappaBalpha pS63 peptide |
Heteromer P25963; P31947; | 100 | 4×CA; 2×CL; 2×MG; 14×GOL; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 in complex with DP005 |
Heteromer P31947; Q04206; | 100 | 2×CL; 2×0V4; | |||
| 14-3-3sigma in complex with a P129beta3P mutated YAP pS127 phosphopeptide |
Heteromer P31947; P46937; | 100 | 8×CL; 4×NA; | |||
| Crystal Structure of human 14-3-3 sigma in Complex with Raf1 peptide (10mer) |
Heteromer P04049; P31947; | 100 | 2×CL; 6×MG; | |||
| 14-3-3 sigma in complex with YAP pS127-peptide |
Heteromer P31947; P46937; | 100 | 8×MG; 8×CL; 2×CA; 6×GOL; | |||
| Cys-45-tethered stabilizer 4 of 14-3-3(sigma)/ERa PPI |
Heteromer P03372; P31947; | 99.13 | 2×MG; 2×T4Q; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1013 |
Heteromer P31947; Q13526; | 100.0 | 2×SGH; 4×CA; 2×CL; | |||
| Cys-45-tethered stabilizer 5 of 14-3-3(sigma)/ERa PPI |
Heteromer P03372; P31947; | 99.13 | 6×MG; 2×T4Z; | |||
| Human 14-3-3 sigma in complex with human Estrogen Receptor alpha peptide |
Heteromer P03372; P31947; | 100.0 | ||||
| Crystal Structure of human 14-3-3 sigma in Complex with Raf1 peptide (6mer) and stabilisator Fusico… |
Heteromer P04049; P31947; | 100 | 2×FSC; 4×CL; 8×MG; | |||
| Small molecular stabilizer for ERalpha and 14-3-3 (1083744) |
Heteromer P03372; P31947; | 100 | 6×MG; 2×NJ3; | |||
| Ternary complex of Estrogen Receptor alpha peptide and 14-3-3 sigma C45 mutant bound to disulfide f… |
Heteromer P03372; P31947; | 99.13 | 4×MG; 2×GE8; | |||
| fragment-linked stabilizer for ERa - 14-3-3 interaction (1074361) |
Heteromer P03372; P31947; | 100 | 6×MG; 2×S0O; | |||
| Cys-42-tethered stabilizer 10 of 14-3-3(sigma)/ERa PPI |
Heteromer P03372; P31947; | 99.13 | 2×MG; 2×T6H; | |||
| fragment-linked stabilizer for ERa - 14-3-3 interaction (1074361) |
Heteromer P03372; P31947; | 100 | 6×MG; 2×U0L; | |||
| fragment-linked stabilizer for ERa - 14-3-3 interaction (1074372) |
Heteromer P03372; P31947; | 100 | 6×MG; 2×RZL; | |||
| 14-3-3 sigma bound to bis-phosphorylated aminopeptidase N (APN, CD13) via canonical and non-canonic… |
Heteromer P15144; P31947; | 100 | 8×NA; 2×CL; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 |
Heteromer P31947; Q04206; | 100 | 4×GOL; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-043 |
Heteromer P31947; Q04206; | 100.0 | 2×V0Q; 2×MG; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-192 |
Heteromer P31947; Q04206; | 100.0 | 2×V2N; 2×V2K; 2×CL; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-046 |
Heteromer P31947; Q04206; | 100.0 | 4×CL; 2×V0T; 2×CA; 2×GOL; 2×PEG; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-180 |
Heteromer P31947; Q04206; | 100.0 | 2×TVB; 6×CA; 4×CL; 2×GOL; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-187 |
Heteromer P31947; Q04206; | 100.0 | 2×TW8; 4×CA; 2×CL; 2×PEG; | |||
| Fragment AZ-003 binding at the TAZpS89/14-3-3 sigma interface |
Heteromer P31947; Q9GZV5; | 100.0 | 6×MG; 4×CL; 2×K48; | |||
| Crystal structure of 14-3-3sigma and a p53 C-terminal 12-mer synthetic phosphopeptide |
Heteromer P04637; P31947; | 100.0 | 2×CA; 2×MG; | |||
| 14-3-3sigma covalently bound to peptide (chloroacetamide-Cys interaction) |
Heteromer P31947; P46937; | 100.0 | 8×MG; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-185 |
Heteromer P31947; Q04206; | 100.0 | 2×UT8; 4×CL; 2×PEG; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-184 |
Heteromer P31947; Q04206; | 100.0 | 2×UVK; 2×CL; 2×MG; 2×PEG; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-182 |
Heteromer P31947; Q04206; | 100.0 | 2×UVZ; 4×CL; 2×MG; 2×PEG; | |||
| 14-3-3 sigma in complex with TAZ peptide and stabilizing fragment TCF199 |
Heteromer P31947; Q9GZV5; | 100.0 | 2×XJF; 6×MG; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-188 |
Heteromer P31947; Q04206; | 100.0 | 2×UST; 4×CL; 2×MG; 2×PEG; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-183 |
Heteromer P31947; Q04206; | 100.0 | 2×UVE; 4×CL; 2×MG; 2×PEG; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-179 |
Heteromer P31947; Q04206; | 100.0 | 2×TQW; 2×GOL; 4×CA; 2×CL; 2×PEG; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-181 |
Heteromer P31947; Q04206; | 100.0 | 2×UVQ; 4×CL; 2×MG; 2×PEG; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-186 |
Heteromer P31947; Q04206; | 100.0 | 2×USW; 4×CL; 2×MG; 2×PEG; | |||
| single soak stabilizer for ERa - 14-3-3 interaction (AZ275) |
Heteromer P03372; P31947; | 100 | 6×MG; 2×SDM; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521 |
Heteromer P31947; Q04206; | 100.0 | 2×L3Y; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound LvD1009 |
Heteromer P31947; Q04206; | 100.0 | 2×TJ8; 2×MG; | |||
| 14-3-3 sigma with RelA/p65 binding site pS281 |
Heteromer P31947; Q04206; | 100 | ||||
| 14-3-3sigma in complex with a S131beta3S mutated YAP pS127 phosphopeptide |
Heteromer P31947; P46937; | 100 | 4×CL; 2×MG; 2×NA; | |||
| single soak stabilizer for ERa - 14-3-3 interaction (AZ555) |
Heteromer P03372; P31947; | 100 | 6×MG; 2×L1T; | |||
| Crystal structure of C-terminal modified Tau peptide-hybrid 4.2e-I with 14-3-3sigma |
Heteromer P10636; P31947; | 100.0 | 7×NA; 2×D3W; 2×CL; | |||
| Crystal structure of 14-3-3 sigma in complex with 20mer Amot-p130 peptide |
Heteromer P31947; Q4VCS5; | 100 | 2×MG; 2×CL; | |||
| Fragment AZ-018 binding at the TAZpS89/14-3-3 sigma interface |
Heteromer P31947; Q9GZV5; | 100 | 2×K5Z; | |||
| Binary complex of 14-3-3 sigma and p53 pT387-peptide |
Heteromer P04637; P31947; | 100.0 | 6×MG; 2×CL; 2×GOL; | |||
| Ternary complex of 14-3-3 sigma (C38N), Estrogen Related Receptor gamma (DBD) phosphopeptide, and d… |
Heteromer P31947; P62508; | 99.57 | 2×MG; 2×CL; 2×O68; | |||
| Ternary complex of 14-3-3 sigma (C38N), Estrogen Related Receptor gamma (DBD) phosphopeptide, and d… |
Heteromer P31947; P62508; | 99.57 | 6×MG; 2×CL; 2×O3W; | |||
| Cys-42-tethered stabilizer 13 of 14-3-3(sigma)/ERa PPI |
Heteromer P03372; P31947; | 99.13 | 6×MG; 2×T6W; | |||
| single soak stabilizer for ERa - 14-3-3 interaction (AZ354) |
Heteromer P03372; P31947; | 100 | 4×MG; 4×LF5; | |||
| Ternary complex of 14-3-3 sigma (C38N), Estrogen Related Receptor gamma (DBD) phosphopeptide, and d… |
Heteromer P31947; P62508; | 99.57 | 4×MG; 2×CL; 2×O4E; | |||
| Crystal structure of 14-3-3 sigma in complex with wild-type Shroom3 |
Heteromer P31947; Q8TF72; | 100.0 | 4×MG; 4×CL; | |||
| Fragment AZ-003 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 100.0 | 4×MG; 2×CL; 2×GOL; 2×K48; | |||
| 14-3-3 sigma in complex with SMAD2 pS465 peptide |
Heteromer P31947; Q15796; | 100.0 | 10×MG; 2×GOL; 2×CL; 2×CA; 2×NA; | |||
| Human 14-3-3 sigma in complex with human MDM2 peptide |
Heteromer P31947; Q00987; | 100 | 2×GOL; 2×PEG; 2×CL; 4×MG; | |||
| Crystal structure of human 14-3-3 sigma in complex with LRRK2 peptide pS935 |
Heteromer P31947; Q5S007; | 100 | 6×CA; 2×CL; | |||
| 14-3-3 sigma with p65 (RelA) binding site pS45 and covalently bound PC2046 |
Heteromer P31947; Q04206; | 100.0 | 2×UQN; 2×GOL; | |||
| Ternary complex of 14-3-3 sigma (C38N), Estrogen Related Receptor gamma (DBD) phosphopeptide, and d… |
Heteromer P31947; P62508; | 99.57 | 6×MG; 2×CL; 2×O85; | |||
| Ternary complex of 14-3-3 sigma, Amot-p130 phosphopeptide, and WQ177 |
Heteromer P31947; Q4VCS5; | 100.0 | 2×0BS; 2×MG; | |||
| Small molecular stabilizer for ERalpha and 14-3-3 (1076394) |
Heteromer P03372; P31947; | 100.0 | 4×MG; 2×NK6; | |||
| Small molecule stabilizer (compound 1) for ERalpha and 14-3-3 |
Heteromer P03372; P31947; | 100 | 4×MG; 2×O6C; | |||
| 14-3-3sigma in complex with a L132beta3L mutated YAP pS127 phosphopeptide |
Heteromer P31947; P46937; | 100 | 2×CL; 2×MG; 2×NA; | |||
| Crystal structure of 14-3-3 sigma in complex with 20mer Amot-p130 peptide and fragment 22 |
Heteromer P31947; Q4VCS5; | 100.0 | 2×K92; 4×CA; 2×CL; 2×MG; | |||
| 14-3-3 sigma in complex with TAZ pS89 peptide and fragment NV3 |
Heteromer P31947; Q9GZV5; | 100.0 | 6×MG; 4×CL; 2×CA; 2×8OE; | |||
| Crystal structure of 14-3-3 sigma in complex with 20mer Amot-p130 peptide and fragment 09 |
Heteromer P31947; Q4VCS5; | 100 | 2×K7N; 4×CA; 2×CL; | |||
| Binary complex of 14-3-3 sigma (C38N) with the Estrogen Related Receptor gamma (DBD) phosphopeptide |
Heteromer P31947; P62508; | 99.57 | 2×MG; 2×CL; | |||
| Small molecular stabilizer for ERalpha and 14-3-3 (1075311) |
Heteromer P03372; P31947; | 100 | 6×MG; 2×MU9; | |||
| Small molecular stabilizer for ERalpha and 14-3-3 (1080299) |
Heteromer P03372; P31947; | 100 | 6×MG; 2×OT0; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-069 |
Heteromer P31947; Q04206; | 100 | 2×CL; 2×TZH; | |||
| Small molecule amidine soak in 14-3-3/ERa (AZ037) |
Heteromer P03372; P31947; | 100 | 6×MG; 2×TG9; | |||
| Small molecule stabilizer (1075481) for ERalpha and 14-3-3 |
Heteromer P03372; P31947; | 100 | 6×MG; 2×O0O; | |||
| Small molecular stabilizer for C-RAF (pS259) and 14-3-3 (1075306) |
Heteromer P04049; P31947; | 100 | 2×CL; 6×MG; 2×O5I; | |||
| Small molecular stabilizer for ERalpha and 14-3-3 (1080297) |
Heteromer P03372; P31947; | 100 | 4×MG; 2×O3F; | |||
| Binary structure of 14-3-3s and PKR phosphopeptide |
Heteromer P19525; P31947; | 100 | 8×MG; | |||
| Small molecule stabilizer for ERalpha and 14-3-3 (1075478) |
Heteromer P03372; P31947; | 100 | 6×MG; 2×N0L; | |||
| Binary structure of 14-3-3s and RND3 phosphopeptide |
Heteromer P31947; P61587; | 99.57 | 8×MG; 2×CL; | |||
| Small molecule stabilizer for ERalpha and 14-3-3 (1080269) |
Heteromer P03372; P31947; | 100 | 2×MG; 2×NUO; | |||
| Small molecular stabilizer for ERalpha and 14-3-3sigma (1074378) |
Heteromer P03372; P31947; | 100 | 6×MG; 2×NR6; | |||
| Small molecular stabilizer for ERalpha and 14-3-3 (1080267) |
Heteromer P03372; P31947; | 100 | 6×MG; 2×NF9; | |||
| fragment-linked stabilizer for ERa - 14-3-3 interaction (AZ210) |
Heteromer P03372; P31947; | 100 | 4×MG; 2×SD7; | |||
| Crystal structure of human 14-3-3 sigma in complex with TASK-3 peptide |
Heteromer P31947; Q9NPC2; | 100 | 6×MG; 2×CL; | |||
| Cys-42-tethered stabilizer 8 of 14-3-3(sigma)/ERa PPI |
Heteromer P03372; P31947; | 99.13 | 4×MG; 2×T5Q; | |||
| Ternary structure of 14-3-3s, RND3 phosphopeptide and dual-reactive compound 10 |
Heteromer P31947; P61587; | 99.57 | 6×MG; 2×CL; 2×OQ3; | |||
| small molecule stabilizer for ERalpha and 14-3-3 (1083743) |
Heteromer P03372; P31947; | 100 | 6×MG; 2×NJC; | |||
| Ternary structure of 14-3-3sigma, PKA-responsive ERa phosphopeptide and Fusicoccin-A |
Heteromer P03372; P31947; | 100 | 6×MG; 2×SIT; | |||
| Small molecular stabilizer for ERalpha and 14-3-3 (1080265) |
Heteromer P03372; P31947; | 100 | 6×MG; 2×NJI; | |||
| Cys-42-tethered stabilizer 6 of 14-3-3(sigma)/ERa PPI |
Heteromer P03372; P31947; | 99.13 | 6×MG; 2×T5N; | |||
| Small molecular stabilizer for ERalpha and 14-3-3 (1080272) |
Heteromer P03372; P31947; | 100 | 4×MG; 2×MVU; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-111 |
Heteromer P31947; Q04206; | 100.0 | 2×UON; 2×UOT; 2×PEG; 2×CL; 2×GOL; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-134 |
Heteromer P31947; Q04206; | 100.0 | 2×UVH; 2×GOL; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-135 |
Heteromer P31947; Q04206; | 100.0 | 2×UHQ; 4×GOL; 2×CA; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-154 |
Heteromer P31947; Q04206; | 100.0 | 2×TZW; | |||
| Ternary complex of 14-3-3 sigma, Amot-p130 phosphopeptide, and WQ180 |
Heteromer P31947; Q4VCS5; | 100.0 | 2×0BL; 2×CL; 4×MG; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-131 |
Heteromer P31947; Q04206; | 100.0 | 2×UVB; 2×MG; 2×CL; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-118 |
Heteromer P31947; Q04206; | 100.0 | 2×CL; 2×GOL; 2×UHW; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-125 |
Heteromer P31947; Q04206; | 100.0 | 2×UWH; 2×CA; 2×CL; 4×GOL; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-124 |
Heteromer P31947; Q04206; | 100.0 | 2×UGN; 2×CA; 2×GOL; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-119 |
Heteromer P31947; Q04206; | 100.0 | 2×CL; 2×CA; 2×UHT; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-142 |
Heteromer P31947; Q04206; | 100.0 | 2×TWQ; | |||
| Ternary complex of 14-3-3 sigma, Amot-p130 phosphopeptide, and WQ162 |
Heteromer P31947; Q4VCS5; | 100.0 | 6×09W; 2×CL; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-117 |
Heteromer P31947; Q04206; | 100.0 | 2×V0W; 2×CL; 2×MG; 6×GOL; | |||
| Crystal structure of 14-3-3 in complex with PyrinpS242 and a protein/peptide interface fragment |
Heteromer O15553; P31947; | 100.0 | 2×463; 2×PE5; 2×MG; 2×CA; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-116 |
Heteromer P31947; Q04206; | 100.0 | 4×CL; 2×CA; 2×GOL; 2×PEG; 2×V1K; | |||
| 14-3-3 sigma in complex with Pin1 binding site pS72 and covalently bound TCF521-026 |
Heteromer P31947; Q13526; | 100.0 | 2×S6B; 8×CA; 2×CL; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-130 |
Heteromer P31947; Q04206; | 100.0 | 2×UVN; 2×CL; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-120 |
Heteromer P31947; Q04206; | 100.0 | 2×UXN; 2×CL; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and covalently bound PC2046 |
Heteromer P31947; Q13526; | 100.0 | 2×TKK; 2×CA; 2×CL; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-128 |
Heteromer P31947; Q04206; | 100.0 | 2×UGQ; 2×CL; 2×CA; 2×GOL; | |||
| Crystal structure of 14-3-3 sigma in complex with 13mer Amot-p130 peptide and fragment 09 |
Heteromer P31947; Q4VCS5; | 100.0 | 2×CL; 2×MG; 2×K7N; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-083 |
Heteromer P31947; Q04206; | 100.0 | 6×V48; 2×CL; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-097 |
Heteromer P31947; Q04206; | 100.0 | 2×V42; 2×CA; 2×CL; | |||
| Structure of 14-3-3 sigma in complex with PADI6 14-3-3 binding motif II |
Heteromer P31947; Q6TGC4; | 100.0 | 2×MG; | |||
| Crystal structure of C-terminal modified Tau peptide-hybrid 4.2f-I with 14-3-3sigma |
Heteromer P10636; P31947; | 100.0 | 5×NA; 2×D3Q; 2×CL; | |||
| Crystal structure of C-terminal modified Tau peptide-hybrid 4.2c-I with 14-3-3sigma |
Heteromer P10636; P31947; | 100.0 | 2×CL; 1×MG; 2×NA; 2×D3K; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-133 |
Heteromer P31947; Q04206; | 100.0 | 2×UGE; 2×PEG; | |||
| Crystal structure of C-terminal modified Tau peptide-hybrid 126B with 14-3-3sigma |
Heteromer P10636; P31947; | 100.0 | 2×CL; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-080 |
Heteromer P31947; Q04206; | 100.0 | 2×V4N; 2×CL; 2×CA; 2×GOL; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-096 |
Heteromer P31947; Q04206; | 100.0 | 2×V3Z; 2×CL; 2×CA; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-127 |
Heteromer P31947; Q04206; | 100.0 | 2×UVT; 2×CL; 2×MG; 2×GOL; | |||
| Small molecule stabilizer for ERalpha and 14-3-3 (1074359) |
Heteromer P03372; P31947; | 100 | 6×MG; 2×N1R; | |||
| Small molecular stabilizer for ERalpha and 14-3-3 (1080266) |
Heteromer P03372; P31947; | 100 | 6×MG; 2×NKL; | |||
| Ternary structure of 14-3-3s, ERRg phosphopeptide and dual-reactive compound 7 |
Heteromer P31947; P62508; | 99.57 | 6×MG; 2×CL; 2×QQ0; | |||
| fragment-linked stabilizer for ERa - 14-3-3 interaction (1075302) |
Heteromer P03372; P31947; | 100 | 6×MG; 2×SOI; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-126 |
Heteromer P31947; Q04206; | 100.0 | 2×UHN; 2×CA; 2×CL; | |||
| Ternary structure of 14-3-3s, ERRg phosphopeptide and dual-reactive compound 8 |
Heteromer P31947; P62508; | 99.57 | 8×MG; 2×CL; 2×QL0; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-129 |
Heteromer P31947; Q04206; | 100.0 | 2×P7T; | |||
| Ternary structure of 14-3-3s, ERRg phosphopeptide and dual-reactive compound 5 |
Heteromer P31947; P62508; | 99.57 | 6×MG; 2×CL; 2×OYI; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-070 |
Heteromer P31947; Q04206; | 100.0 | 2×GOL; 2×CA; 2×UHZ; 2×CL; 2×PEG; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-153 |
Heteromer P31947; Q04206; | 100.0 | 4×U1B; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-157 |
Heteromer P31947; Q04206; | 100.0 | 2×V2E; | |||
| Ternary structure of 14-3-3s, ERRg phosphopeptide and dual-reactive compound 6 |
Heteromer P31947; P62508; | 99.56 | 6×MG; 2×CL; 2×QL9; | |||
| Small molecular stabilizer for ERalpha and 14-3-3 (1074202 - non covalent) |
Heteromer P03372; P31947; | 100 | 6×MG; 2×O4I; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-132 |
Heteromer P31947; Q04206; | 100.0 | 2×GOL; 2×CL; 2×UG8; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-123 |
Heteromer P31947; Q04206; | 100 | 2×P7E; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-121 |
Heteromer P31947; Q04206; | 100.0 | 2×UWK; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-122 |
Heteromer P31947; Q04206; | 100.0 | 2×UWQ; 2×CA; | |||
| 14-3-3 Sigma in complex with phosphorylated MLF1 peptide |
Heteromer P31947; P58340; | 100.0 | 4×CA; 4×MG; 2×CL; | |||
| FC-J stabilizer for ERa and 14-3-3 |
Heteromer P03372; P31947; | 100 | 6×MG; 2×SIY; | |||
| Ternary complex of 14-3-3 sigma, Estrogen Receptor alfa phosphopeptide, and WQ178 |
Heteromer P03372; P31947; | 100.0 | 6×MG; 2×CL; 4×0B7; | |||
| A novel phospho-switch in the linker region of the snail zinc finger protein which regulates 14-3-3… |
Heteromer O95863; P31947; | 99.57 | 4×MG; 2×GOL; | |||
| Cys-42-tethered stabilizer 9 of 14-3-3(sigma)/ERa PPI |
Heteromer P03372; P31947; | 99.13 | 6×MG; 2×T5W; | |||
| Small molecular stabilizer for ERalpha and 14-3-3 (1080273) |
Heteromer P03372; P31947; | 100 | 6×MG; 2×NQU; | |||
| Cys-42-tethered stabilizer 7 of 14-3-3(sigma)/ERa PPI |
Heteromer P03372; P31947; | 99.13 | 6×MG; 2×T5T; | |||
| Crystal structure of C-terminal modified Tau peptide-hybrid 4.2f-II with 14-3-3sigma |
Heteromer P10636; P31947; | 100.0 | 2×CL; 4×NA; 2×D4K; | |||
| Crystal structure of 14-3-3 sigma in complex with Shroom3 P1244L |
Heteromer P31947; Q8TF72; | 100.0 | 4×MG; 4×CL; | |||
| Crystal structure of human 14-3-3 sigma in complex with LRRK2 peptide pS910 |
Heteromer P31947; Q5S007; | 100 | 4×CA; 2×CL; 2×NA; | |||
| Small molecule amidine soak in 14-3-3/ERa (AZ132) |
Heteromer P03372; P31947; | 100 | 6×MG; 2×KM8; | |||
| FC-NAc stabilizer of 14-3-3 and ERalpha |
Heteromer P03372; P31947; | 100 | 6×MG; 2×EZ5; | |||
| Fragment AZ-010 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 100.0 | 2×KM8; | |||
| 14-3-3 in complex with Pyrinp pS242 |
Heteromer O15553; P31947; | 100.0 | ||||
| 14-3-3sigma in complex with a A130beta3A mutated YAP pS127 phosphopeptide |
Heteromer P31947; P46937; | 100 | 2×CL; 2×MG; 2×NA; | |||
| Cys-42-tethered stabilizer 11 of 14-3-3(sigma)/ERa PPI |
Heteromer P03372; P31947; | 99.13 | 6×MG; 2×T6N; | |||
| Human 14-3-3 sigma in complex with human Estrogen Receptor alpha peptide and ligands Fusicoccin-A a… |
Heteromer P03372; P31947; | 100.0 | 2×FSC; 2×UGH; | |||
| FC-31 stabilizer of 14-3-3 and ERalpha |
Heteromer P03372; P31947; | 100 | 6×MG; 2×SJC; | |||
| 14-3-3 Sigma in complex with phosphorylated c-Jun peptide |
Heteromer P05412; P31947; | 100.0 | 4×MG; 4×CA; | |||
| small molecule stabilizer (compound 1) for C-RAF pS259 and 14-3-3 |
Heteromer P04049; P31947; | 100 | 2×CL; 6×MG; 2×O6C; | |||
| Small molecular stabilizer for ERalpha and 14-3-3 (1076405) |
Heteromer P03372; P31947; | 100 | 6×MG; 2×ND9; | |||
| Small molecular stabilizer for ERalpha and 14-3-3 (1075310) |
Heteromer P03372; P31947; | 100 | 4×MG; 2×MVO; | |||
| Small molecular stabilizer for ERalpha and 14-3-3 (1076402) |
Heteromer P03372; P31947; | 100 | 6×MG; 2×NQ9; | |||
| Small molecule stabilizer for ERalpha and 14-3-3 (1080298) |
Heteromer P03372; P31947; | 100 | 6×MG; 2×O2X; | |||
| Small molecule stabilizer for ERalpha and 14-3-3 (1076406) |
Heteromer P03372; P31947; | 100 | 6×MG; 2×NQ0; | |||
| 14-3-3 Sigma in complex with phosphorylated (Thr391) Gab2 peptide |
Heteromer P31947; Q9UQC2; | 100 | 4×MG; | |||
| 14-3-3 Sigma in complex with phosphorylated camkk2{pS511} peptide |
Heteromer P31947; Q96RR4; | 100 | 6×MG; 2×CL; | |||
| 14-3-3 sigma in complex with Pin1 binding site pS72 |
Heteromer P31947; Q13526; | 100 | 4×CA; 4×CL; | |||
| Small molecular stabilizer for ERalpha and 14-3-3 (1076397) |
Heteromer P03372; P31947; | 100 | 6×MG; 2×MRF; | |||
| deAc-FC stabilizer of 14-3-3 and ERalpha |
Heteromer P03372; P31947; | 100 | 6×MG; 2×SIT; | |||
| Small molecular stabilizer for ERalpha and 14-3-3 (1080294) |
Heteromer P03372; P31947; | 100 | 2×MG; 2×NIB; | |||
| Small molecular stabilizer for ERalpha and 14-3-3 (1076398) |
Heteromer P03372; P31947; | 100 | 4×MG; 2×NQL; | |||
| Ternary complex of 14-3-3 sigma, Amot-p130 phosphopeptide, and WQ136 |
Heteromer P31947; Q4VCS5; | 100.0 | 6×0AW; 2×BME; 2×MG; | |||
| Crystal structure of 14-3-3 sigma in complex with 13mer Amot-p130 peptide and fragment 40 |
Heteromer P31947; Q4VCS5; | 100.0 | 2×UJW; 2×CL; | |||
| 14-3-3 Sigma in complex with phosphorylated CAMKK2 peptide |
Heteromer P31947; Q96RR4; | 100.0 | 4×MG; 2×CA; | |||
| Small molecular stabilizer for ERalpha and 14-3-3 (1080300) |
Heteromer P03372; P31947; | 100 | 6×MG; 2×NG9; | |||
| Crystal structure of C-terminal modified Tau peptide-hybrid 4.2b with 14-3-3sigma |
Heteromer P10636; P31947; | 100.0 | 2×CL; 4×NA; 2×D4H; | |||
| 14-3-3 Sigma in complex with phosphorylated caspase{pS164} peptide |
Heteromer P31947; P42575; | 100.0 | 8×MG; 2×CL; | |||
| 14-3-3sigma in complex with SLP76pS376 phosphopeptide crystal structure |
Heteromer P31947; Q13094; | 100 | 10×MG; | |||
| FC-J acetonide stabilizer of 14-3-3 and ERalpha |
Heteromer P03372; P31947; | 100 | 6×MG; 2×SJ4; | |||
| Fragment AZ-009 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 100.0 | 2×KLZ; 2×MG; | |||
| 14-3-3 Sigma in complex with phosphorylated caspase{pS139} peptide |
Heteromer P31947; P42575; | 100.0 | 6×MG; 2×CL; | |||
| Fragment AZ-015 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 100.0 | 4×MG; 2×CL; 2×GOL; 2×K6B; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1005 |
Heteromer P31947; Q13526; | 100.0 | 2×UG5; 2×CA; | |||
| Small molecular stabilizer for ERalpha and 14-3-3 (1080293) |
Heteromer P03372; P31947; | 100 | 6×MG; 2×O3O; | |||
| Small molecule stabilizer (compound 3) for FOXO1 and 14-3-3 |
Heteromer P31947; Q12778; | 100 | 4×MG; 2×L70; | |||
| Small molecular stabilizer for ERalpha and 14-3-3 (1080291) |
Heteromer P03372; P31947; | 100 | 6×MG; 2×NJR; | |||
| Small molecular stabilizer for ERalpha and 14-3-3sigma (1080268) |
Heteromer P03372; P31947; | 100 | 6×MG; 2×M79; | |||
| Small molecule stabilizer for ERalpha and 14-3-3 (1075297) |
Heteromer P03372; P31947; | 100 | 6×MG; 2×O6L; | |||
| fragment-linked stabilizer for ERa - 14-3-3 interaction (1075287) |
Heteromer P03372; P31947; | 100 | 2×S1I; | |||
| Small molecular stabilizer for ERalpha and 14-3-3 (1080295) |
Heteromer P03372; P31947; | 100 | 4×MG; 2×NE9; | |||
| fragment-linked stabilizer for ERa - 14-3-3 interaction (1075296) |
Heteromer P03372; P31947; | 100 | 2×S3U; | |||
| Fragment-linked stabilizer for ERa - 14-3-3 interaction (1075293) |
Heteromer P03372; P31947; | 100 | 2×S2E; | |||
| fragment-linked stabilizer for ERa - 14-3-3 interaction (1074398) |
Heteromer P03372; P31947; | 100 | 2×S8O; | |||
| Small molecule stabilizer (compound 7) for C-RAF and 14-3-3 |
Heteromer P04049; P31947; | 100 | 2×CL; 4×MG; 2×L6L; | |||
| fragment-linked stabilizer for ERa - 14-3-3 interaction (1074397) |
Heteromer P03372; P31947; | 100 | 6×MG; 2×S0U; | |||
| Fragment-linked stabilizer for 14-3-3 and ERa (1075298) |
Heteromer P03372; P31947; | 100 | 2×RZT; | |||
| fragment-linked stabilizer for ERa - 14-3-3 interaction (1074395) |
Heteromer P03372; P31947; | 100 | 2×SE3; | |||
| fragment-linked stabilizer for ERa - 14-3-3 interaction (1075316) |
Heteromer P03372; P31947; | 100 | 6×MG; 2×S7R; | |||
| fragment-linked stabilizer for ERa - 14-3-3 interaction (1074393) |
Heteromer P03372; P31947; | 100 | 2×S3I; | |||
| fragment-linked stabilizer for ERa - 14-3-3 interaction (1074386) |
Heteromer P03372; P31947; | 100 | 2×RYR; | |||
| Small molecule stabilizer (compound 8) for C-RAF and 14-3-3 |
Heteromer P04049; P31947; | 100 | 2×CL; 4×MG; 2×O56; | |||
| fragment-linked stabilizer for ERa - 14-3-3 interaction (1074399) |
Heteromer P03372; P31947; | 100 | 2×S1R; | |||
| fragment-linked stabilizer for ERa - 14-3-3 interactions (1075288) |
Heteromer P03372; P31947; | 100 | 2×S7I; | |||
| fragment-linked stabilizer for ERa - 14-3-3 interaction (1074392) |
Heteromer P03372; P31947; | 100 | 2×RZC; | |||
| fragment-linked stabilizer for ERa - 14-3-3 interaction (1075292) |
Heteromer P03372; P31947; | 100 | 2×S86; | |||
| Small molecule stabilizer for ERalpha and 14-3-3 (1075306) |
Heteromer P03372; P31947; | 100 | 6×MG; 2×O5I; | |||
| fragment-linked stabilizer for ERa - 14-3-3 interaction (1075313) |
Heteromer P03372; P31947; | 100 | 2×RY0; | |||
| Small molecule stabilizer (compound 2) for FOXO1 and 14-3-3 |
Heteromer P31947; Q12778; | 100 | 4×MG; 2×L7L; | |||
| 14-3-3sigma in complex with a R124beta3R mutated YAP pS127 phosphopeptide |
Heteromer P31947; P46937; | 100 | 2×CL; 2×MG; 4×NA; | |||
| fragment-linked stabilizer for ERa - 14-3-3 interaction (1074388) |
Heteromer P03372; P31947; | 100 | 2×S2U; | |||
| Small molecular stabilizer for ERalpha and 14-3-3 (1076403) |
Heteromer P03372; P31947; | 100 | 6×MG; 2×MV3; | |||
| Small molecule stabilizer (compound 5) for C-RAF(pS259) and 14-3-3 |
Heteromer P04049; P31947; | 100 | 6×MG; 2×L7U; | |||
| Ternary complex of 14-3-3 sigma, Estrogen Receptor alfa phosphopeptide, and WQ162 |
Heteromer P03372; P31947; | 100.0 | 4×09W; 2×BME; 2×CL; 4×MG; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and covalently bound CV1040 |
Heteromer P31947; Q13526; | 100.0 | 2×T85; 4×MG; | |||
| Small molecule stabilizer for 14-3-3/ChREBP (Cmd1-soaking) |
Heteromer P31947; Q9NP71; | 100.0 | 6×MG; 2×OQE; | |||
| Fragment AZ-024 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 100.0 | 2×MG; 2×CL; 2×K7Q; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and bound Fusicoccin A |
Heteromer P31947; Q13526; | 100.0 | 2×FSC; 2×MG; | |||
| 14-3-3 in complex with PyrinpS208pS242 |
Heteromer O15553; P31947; | 100.0 | 1×B3P; | |||
| FC-THF stabilizer of 14-3-3 and ERalpha |
Heteromer P03372; P31947; | 100 | 2×FC7; | |||
| Fragment AZ-025 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 100.0 | 4×MG; 2×CL; 2×K7N; | |||
| Fragment AZ-026 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 100.0 | 4×MG; 2×CL; 2×K92; | |||
| Small molecular stabilizer for ERalpha and 14-3-3 (1075305) |
Heteromer P03372; P31947; | 100 | 6×MG; 2×O49; | |||
| 14-3-3 sigma in complex with SMAD4 pS403 peptide |
Heteromer P31947; Q13485; | 100.0 | 2×GOL; 4×NA; 4×MG; 2×CA; | |||
| 14-3-3 sigma bound to canonical mono-phosphorylated aminopeptidase N (APN, CD13) binding motif |
Heteromer P15144; P31947; | 100 | 4×NA; 2×CA; 4×MG; | |||
| Fragment AZ-011 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 100.0 | 4×MG; 2×CL; 2×LFB; | |||
| Fragment AZ-012 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 100.0 | 2×CL; 4×LF5; | |||
| Fragment AZ-014 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 100.0 | 4×MG; 2×CL; 2×K6N; | |||
| Fragment AZ-017 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 100.0 | 4×MG; 2×CL; 4×LFQ; | |||
| Crystal structure of 14-3-3sigma in complex with a PAK6 pT99 phosphopeptide |
Heteromer P31947; Q9NQU5; | 100.0 | 4×CA; 2×CL; 2×MG; 6×NA; | |||
| Fragment AZ-020 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 100.0 | 2×K65; | |||
| 14-3-3 sigma sirtuin-1 phospho-peptide complex |
Heteromer P31947; Q96EB6; | 100.0 | 2×MG; 2×CL; | |||
| FC-NAg stabilizer of 14-3-3 and ERalpha |
Heteromer P03372; P31947; | 100 | 6×MG; 2×SKR; | |||
| Crystal structure of human 14-3-3 sigma C38N/N166H in complex with TASK-3 peptide and stabilizer fu… |
Heteromer P31947; Q9NPC2; | 99.13 | 2×FSC; 2×CL; 4×MG; | |||
| fragment-linked stabilizer for ERa - 14-3-3 interaction (1047455) |
Heteromer P03372; P31947; | 100 | 2×S6X; | |||
| Fragment AZ-002 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 100.0 | 2×KLE; 2×CA; 4×MG; | |||
| Fragment AZ-007 binding at a primary and secondary binding site of the the p53pT387/14-3-3 sigma co… |
Heteromer P04637; P31947; | 100.0 | 4×KLB; 2×CA; 4×MG; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1012 |
Heteromer P31947; Q13526; | 100.0 | 2×TLK; 2×CA; 2×CL; 2×MG; | |||
| Fragment AZ-004 binding at a primary and secondary site in a p53pT387/14-3-3 complex |
Heteromer P04637; P31947; | 100.0 | 6×L1T; 2×CA; | |||
| Small molecular stabilizer for C-RAF (pS259) and 14-3-3 (1075297) |
Heteromer P04049; P31947; | 100 | 2×CL; 4×MG; 2×O6L; | |||
| Crystal structure of human 14-3-3 sigma C38N/N166H in complex with TASK-3 Peptide and stabilizer fu… |
Heteromer P31947; Q9NPC2; | 99.13 | 2×FSC; 2×CL; 4×MG; 2×CA; | |||
| Crystal structure of human 14-3-3 sigma C38V/N166H in complex with TASK-3 peptide |
Heteromer P31947; Q9NPC2; | 99.13 | 8×MG; 8×CL; 2×CA; | |||
| Ternary complex of Estrogen Receptor alpha peptide and 14-3-3 sigma C42 mutant bound to disulfide f… |
Heteromer P03372; P31947; | 99.13 | 6×MG; 2×G8Q; | |||
| Cys-45-tethered stabilizer 3 of 14-3-3(sigma)/ERa PPI |
Heteromer P03372; P31947; | 99.13 | 4×MG; 2×T4W; | |||
| 14-3-3 isoform sigma in complex with a phosphorylated C-RAF peptide |
Heteromer P04049; P31947; | 100.0 | ||||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-110 |
Heteromer P31947; Q04206; | 100.0 | 2×S9E; 2×PEG; | |||
| Crystal structure of C-terminal modified Tau peptide-hybrid 3.2d with 14-3-3sigma |
Heteromer P10636; P31947; | 100.0 | 2×CL; 2×MG; 8×NA; 2×60H; | |||
| 14-3-3 sigma in complex with SMAD3 pS423 peptide |
Heteromer P31947; P84022; | 100.0 | 6×MG; 6×CL; 2×CA; 2×GOL; 2×NA; | |||
| Crystal structure of human 14-3-3 sigma in complex with a Tau-protein peptide surrounding pS324 |
Heteromer P10636; P31947; | 99.55 | 4×MG; 2×CA; 2×CL; | |||
| Crystal structure of C-terminal modified Tau peptide-hybrid 109B with 14-3-3sigma |
Heteromer P10636; P31947; | 100.0 | 1×49F; | |||
| co-soak stabilizers for ERa - 14-3-3 interaction (884_AZ275) |
Heteromer P03372; P31947; | 99.57 | 6×MG; 2×GEH; 2×SDM; | |||
| Ternary complex of 14-3-3 sigma, Usp8pS718 phosphopeptide and small molecule stabilizer |
Heteromer P31947; P40818; | 100 | 2×O6C; | |||
| fragment-linked stabilizer for ERa - 14-3-3 interaction (1047648) |
Heteromer P03372; P31947; | 100 | 2×S6O; | |||
| Crystal structure of 14-3-3sigma in complex with a RapGef2 pT740 phosphopeptide |
Heteromer P31947; Q9Y4G8; | 100.0 | 2×CA; 2×CL; 10×NA; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and covalently bound TCF521-011 |
Heteromer P31947; Q13526; | 100.0 | 2×P5N; 4×CA; 2×CL; | |||
| 14-3-3 Sigma in complex with phosphorylated SOS1 peptide |
Heteromer P31947; Q07889; | 100.0 | 6×MG; 8×CL; 2×CA; | |||
| Crystal structure of 14-3-3sigma in complex with a PAK6 pT99 phosphopeptide stabilized by semi-synt… |
Heteromer P31947; Q9NQU5; | 100.0 | 2×HY5; 2×CL; 4×NA; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1019 |
Heteromer P31947; Q13526; | 100.0 | 2×TL8; 6×CA; 2×CL; | |||
| Crystal structure of 14-3-3 sigma in complex with 13mer Amot-p130 peptide |
Heteromer P31947; Q4VCS5; | 100.0 | 2×CL; 2×MG; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1006 |
Heteromer P31947; Q13526; | 100.0 | 2×UG2; 2×CL; | |||
| 14-3-3 Sigma in complex with phosphorylated PLN peptide |
Heteromer P26678; P31947; | 100.0 | 6×MG; 2×CL; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1009 |
Heteromer P31947; Q13526; | 100.0 | 2×TJ8; 2×MG; | |||
| 14-3-3 sigma in complex with hDM2-186 peptide |
Heteromer P31947; Q00987; | 100.0 | 6×IOD; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1002F1 |
Heteromer P31947; Q13526; | 100.0 | 2×UPQ; 2×CA; 2×CL; 4×PEG; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1017 |
Heteromer P31947; Q13526; | 100.0 | 2×TJB; 2×MG; | |||
| Crystal structure of human 14-3-3 sigma in complex with TASK-3 peptide and stabilizer Fusicoccin H |
Heteromer P31947; Q9NPC2; | 100.0 | 8×MG; 2×CL; 2×GOL; 2×0DV; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and covalently bound TCF521-110 |
Heteromer P31947; Q13526; | 100.0 | 2×S9E; 2×CA; | |||
| small molecule stabilizer for ERalpha and 14-3-3 (1074202) |
Heteromer P03372; P31947; | 100 | 6×MG; 2×O4I; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-044 |
Heteromer P31947; Q04206; | 100 | 2×CL; 2×TZK; 2×GOL; 4×CA; 2×MG; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-028 |
Heteromer P31947; Q04206; | 100 | 2×CL; 2×P5Q; | |||
| Crystal structure of human 14-3-3 sigma C38V/N166H in complex with TASK-3 peptide and stabilizer Fu… |
Heteromer P31947; Q9NPC2; | 99.13 | 2×FJA; 6×MG; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-033 |
Heteromer P31947; Q04206; | 100 | 2×CL; 2×P6Z; | |||
| Crystal structure of 14-3-3 sigma in complex with LDB1 phosphopeptide and stabilizer Fusicoccin-A |
Heteromer P31947; Q86U70; | 100 | 2×FSC; 2×CL; 4×MG; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-037 |
Heteromer P31947; Q04206; | 100 | 2×CL; 2×P6H; | |||
| Small molecule stabilizer for 14-3-3/ChREBP (Cmd 30) |
Heteromer P31947; Q9NP71; | 100 | 2×U0U; | |||
| Crystal structure of 14-3-3 sigma in complex with LDB1 phosphopeptide |
Heteromer P31947; Q86U70; | 100 | 4×CA; 2×CL; 2×MG; 2×GOL; | |||
| Small molecular stabilizer for ERalpha and 14-3-3 (1075299) |
Heteromer P03372; P31947; | 100 | 6×MG; 2×O3T; | |||
| Crystal structure of 14-3-3 sigma in complex with SSBP4 phosphopeptide |
Heteromer P31947; Q9BWG4; | 100 | 4×MG; 2×CL; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-011 |
Heteromer P31947; Q04206; | 100 | 2×CL; 2×P5N; | |||
| Crystal structure of 14-3-3 sigma in complex with NPM1 phosphopeptide |
Heteromer P06748; P31947; | 100 | 2×CL; 6×MG; | |||
| Crystal structure of human 14-3-3 sigma C38V/N166H in complex with TASK-3 peptide and stabilizer Co… |
Heteromer P31947; Q9NPC2; | 99.13 | 2×CX7; 4×MG; | |||
| Crystal structure of 14-3-3 sigma in complex with RIPK2 phosphopeptide |
Heteromer O43353; P31947; | 100 | 2×CA; 6×MG; | |||
| Crystal structure of 14-3-3 sigma in complex with PKR phosphopeptide |
Heteromer P19525; P31947; | 100 | 4×MG; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and covalently bound PC2068A |
Heteromer P31947; Q13526; | 100.0 | 2×TKH; 2×CA; 2×CL; | |||
| Ternary complex of 14-3-3 sigma, NotchpS1917 phosphopeptide, and WQ178 |
Heteromer P31947; Q99466; | 100.0 | 2×CL; 2×MG; 2×0B7; | |||
| Crystal structure of 14-3-3sigma and a p53 C-terminal 12-mer synthetic phosphopeptide |
Heteromer P04637; P31947; | 100.0 | 2×CL; 2×MG; | |||
| Ternary complex of 14-3-3 sigma, p27pT198 phosphopeptide, and WQ178 |
Heteromer P31947; P46527; | 100.0 | 4×0B7; 4×MG; 2×CL; | |||
| Ternary complex of 14-3-3 sigma, NotchpS1917 phosphopeptide, and WQ136 |
Heteromer P31947; Q99466; | 100.0 | 2×CL; 2×MG; 6×0AW; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-175 |
Heteromer P31947; Q04206; | 100.0 | 2×CL; 2×TWE; | |||
| Crystal structure of C-terminal modified Tau peptide-hybrid 201D with 14-3-3sigma |
Heteromer P10636; P31947; | 100.0 | ||||
| Crystal structure of C-terminal modified Tau peptide-hybrid 201D with 14-3-3sigma |
Heteromer P10636; P31947; | 100.0 | 1×49F; | |||
| Ternary complex of 14-3-3 sigma, Pin1pS72 phosphopeptide, and WQ136 |
Heteromer P31947; Q13526; | 100.0 | 6×0AW; 2×CL; | |||
| Ternary complex of 14-3-3 sigma, p27pT198 phosphopeptide, and WQ147 |
Heteromer P31947; P46527; | 100.0 | 6×MG; 2×CL; 2×0I2; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-025 |
Heteromer P31947; Q04206; | 100.0 | 2×CL; 2×L3S; | |||
| Ternary complex of 14-3-3 sigma, Pin1pS72 phosphopeptide, and WQ162 |
Heteromer P31947; Q13526; | 100.0 | 4×09W; 2×CL; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-158 |
Heteromer P31947; Q04206; | 100.0 | 2×CL; 2×V2Q; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1032 |
Heteromer P31947; Q13526; | 100.0 | 6×UPK; 4×GOL; 4×PEG; 2×MG; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-161 |
Heteromer P31947; Q04206; | 100.0 | 4×CL; 2×V32; 2×MG; 2×PEG; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-042 |
Heteromer P31947; Q04206; | 100.0 | 4×CL; 2×V1E; 2×CA; 2×GOL; | |||
| Ternary complex of 14-3-3 sigma, p27pT198 phosphopeptide, and WQ136 |
Heteromer P31947; P46527; | 100.0 | 6×0AW; 4×MG; 2×CL; 2×CA; | |||
| Crystal structure of 14-3-3 sigma in complex with 13mer Amot-p130 peptide and fragment 41 |
Heteromer P31947; Q4VCS5; | 100.0 | 2×K8W; 2×CA; 2×CL; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-166 |
Heteromer P31947; Q04206; | 100.0 | 2×CL; 2×V3N; | |||
| 14-3-3 sigma in complex with TAZ pS89 peptide and fragment NV2 |
Heteromer P31947; Q9GZV5; | 100.0 | 4×MG; 2×CL; 2×8OB; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1007 |
Heteromer P31947; Q13526; | 100.0 | 2×JFS; 2×CA; 2×MG; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-176 |
Heteromer P31947; Q04206; | 100.0 | 4×CL; 2×V4H; 2×CA; 2×PEG; 2×GOL; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-164 |
Heteromer P31947; Q04206; | 100.0 | 4×CL; 2×V3B; 4×PEG; 2×MG; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-173 |
Heteromer P31947; Q04206; | 100.0 | 4×CL; 2×V3W; 2×CA; 2×PEG; | |||
| Crystal structure of 14-3-3 sigma in complex with PKR phosphopeptide and stabilizer Fusicoccin-A |
Heteromer P19525; P31947; | 100.0 | 2×FSC; 4×MG; | |||
| Ternary complex of 14-3-3 sigma, NotchpS1917 phosphopeptide, and WQ162 |
Heteromer P31947; Q99466; | 100.0 | 2×CL; 2×09W; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-041 |
Heteromer P31947; Q04206; | 100.0 | 6×CL; 2×V1Q; 2×PEG; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-159 |
Heteromer P31947; Q04206; | 100.0 | 2×CL; 2×V2T; 2×GOL; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-167 |
Heteromer P31947; Q04206; | 100.0 | 4×CL; 2×V3Q; 2×MG; 2×GOL; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-168 |
Heteromer P31947; Q04206; | 100.0 | 4×CL; 2×V3T; 2×CA; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-085 |
Heteromer P31947; Q04206; | 100.0 | 4×CL; 2×V4B; 2×CA; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-165 |
Heteromer P31947; Q04206; | 100.0 | 4×CL; 2×V3K; 2×GOL; 2×CA; | |||
| Small molecular stabilizer for ERalpha and 14-3-3 (1075300) |
Heteromer P03372; P31947; | 100.0 | 4×MG; 2×O4R; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-160 |
Heteromer P31947; Q04206; | 100.0 | 4×CL; 2×V2W; 2×MG; 2×GOL; | |||
| Ternary complex of 14-3-3 sigma, p27pT198 phosphopeptide, and WQ162 |
Heteromer P31947; P46527; | 100.0 | 4×09W; 4×MG; 2×CL; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1016 |
Heteromer P31947; Q13526; | 100.0 | 2×TQK; 2×CA; 2×CL; | |||
| Small molecule stabilizer for ERalpha and 14-3-3 (1074210) |
Heteromer P03372; P31947; | 100 | 4×MG; 2×ODC; | |||
| Fragment AZ-010 binding at the TAZpS89/14-3-3 sigma interface |
Heteromer P31947; Q9GZV5; | 100.0 | 2×KM8; | |||
| Ternary complex of Estrogen Receptor alpha peptide and 14-3-3 sigma C42 mutant bound to disulfide f… |
Heteromer P03372; P31947; | 99.13 | 6×MG; 2×G8T; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and covalently bound PC2068B |
Heteromer P31947; Q13526; | 100.0 | 2×TJK; 2×CA; 2×CL; 2×MG; | |||
| 14-3-3 sigma in complex with TAZ pS89 peptide and fragment NV1 |
Heteromer P31947; Q9GZV5; | 100.0 | 6×MG; 2×CL; 2×NV1; | |||
| Crystal structure of 14-3-3 sigma in complex with Ataxin-1 Ser776 phosphopeptide |
Heteromer P31947; P54253; | 100 | 2×MG; 2×CL; | |||
| Ternary complex of Estrogen Receptor alpha peptide and 14-3-3 sigma C42 mutant bound to disulfide f… |
Heteromer P03372; P31947; | 99.13 | 6×MG; 2×G4Z; | |||
| 14-3-3 sigma in complex with TAZ pS89 peptide |
Heteromer P31947; Q9GZV5; | 100.0 | 6×MG; 6×CL; | |||
| Ternary complex of 14-3-3 sigma, Estrogen Receptor alfa phosphopeptide, and WQ136 |
Heteromer P03372; P31947; | 100.0 | 6×0AW; 4×MG; 2×CL; 2×BME; | |||
| Fragment AZ-005 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 100.0 | 6×MG; 2×CA; 2×KM2; | |||
| 14-3-3sigma in complex with a A130beta3A and Q133beta3Q mutated YAP pS127 phosphopeptide |
Heteromer P31947; P46937; | 100 | 2×CA; 4×CL; 6×NA; | |||
| Crystal structure of an Estrogen Receptor alpha 8-mer phosphopeptide in complex with 14-3-3sigma st… |
Heteromer P03372; P31947; | 100.0 | 4×MG; 4×NE5; | |||
| 14-3-3sigma in complex with BLNKpT152 phosphopeptide crystal structure |
Heteromer P31947; Q8WV28; | 100 | 6×MG; | |||
| Fragment AZ-018 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 100.0 | 2×K5Z; 2×CA; | |||
| Fragment AZ-021 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 100.0 | 4×MG; 2×CL; 2×GOL; 2×K6W; | |||
| Fragment AZ-023 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 100 | 4×MG; 2×CL; 2×K6T; | |||
| Fragment AZ-022 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 100.0 | 2×MG; 2×CL; 2×GOL; 4×K6Z; | |||
| Fragment AZ-006 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 100 | 4×MG; 2×CL; 2×GOL; 2×JT2; | |||
| Fragment AZ-016 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 100.0 | 6×MG; 2×CL; 4×K8W; | |||
| Fragment AZ-006 binding at the TAZpS89/14-3-3 sigma interface |
Heteromer P31947; Q9GZV5; | 100 | 4×JT2; | |||
| Fragment AZ-019 binding at the TAZpS89/14-3-3 sigma interface |
Heteromer P31947; Q9GZV5; | 100 | 2×KDK; 2×CA; 2×NA; | |||
| Crystal structure of 14-3-3 sigma in complex with Phosphorylated and Farnesylated Rnd3 peptide |
Heteromer P31947; P61587; | 100 | 2×CL; 2×MG; 2×FAR; | |||
| 14-3-3sigma in complex with a P129beta3P and L132beta3L mutated YAP pS127 phosphopeptide |
Heteromer P31947; P46937; | 100 | 4×CA; 2×CL; | |||
| Crystal structure of human 14-3-3 sigma in complex with TASK-3 peptide and stabilisator Fusicoccin A |
Heteromer P31947; Q9NPC2; | 100 | 2×FSC; 2×CL; 2×CA; 8×MG; | |||
| Fragment AZ-013 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 100 | 6×MG; 2×CL; 2×LJW; | |||
| Crystal structure of human 14-3-3 sigma C38N/N166H in complex with TASK-3 peptide and stabilizer Fu… |
Heteromer P31947; Q9NPC2; | 99.13 | 2×FW1; 2×CL; 8×MG; | |||
| Crystal structure of human 14-3-3 sigma in complex with TASK-3 peptide and stabilizer 16-O-Me-FC-H |
Heteromer P31947; Q9NPC2; | 100.0 | 2×0V4; 4×MG; | |||
| 14-3-3 sigma with AS160 binding site pT642 |
Heteromer O60343; P31947; | 100.0 | 4×NHE; 4×MG; | |||
| Crystal structure of human 14-3-3 sigma in complex with a Tau-protein peptide surrounding pS214 |
Heteromer P10636; P31947; | 100.0 | 2×CL; 4×MG; 6×CA; 3×GOL; | |||
| 14-3-3 sigma in complex with FOXO1 pS256 peptide |
Heteromer P31947; Q12778; | 100.0 | 2×GOL; 1×B3P; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1008 |
Heteromer P31947; Q13526; | 100.0 | 2×UFH; 4×CA; 2×CL; | |||
| 14-3-3 sigma with Pin1 binding site pS72 and covalently bound LvD1011 |
Heteromer P31947; Q13526; | 100.0 | 2×TLQ; 4×CA; 2×CL; 2×NA; | |||
| Fragment AZ-001 binding at the p53pT387/14-3-3 sigma interface and additional sites |
Heteromer P04637; P31947; | 100.0 | 8×MG; 2×CL; 8×KTW; 2×GOL; 2×CA; | |||
| Ternary complex of 14-3-3 sigma, Amot-p130 phosphopeptide, and WQ178 |
Heteromer P31947; Q4VCS5; | 100.0 | 4×0B7; 4×MG; | |||
| Binary complex of 14-3-3 sigma (C38N) with the Estrogen Related Receptor gamma (LBD) phosphopeptide |
Heteromer P31947; P62508; | 100 | 6×MG; | |||
| Crystal structure of human 14-3-3 sigma C38N/N166H in complex with TASK-3 peptide |
Heteromer P31947; Q9NPC2; | 99.13 | 2×CL; 6×MG; | |||
| 14-3-3sigma in complex with a TASK3 peptide stabilized by semi-synthetic natural product FC-NAc |
Heteromer P31947; Q9NPC2; | 100.0 | 2×EZ5; 2×CL; 4×NA; | |||
| 14-3-3 Sigma in complex with phosphorylated (pS210) Gab2 peptide |
Heteromer P31947; Q9UQC2; | 100.0 | 4×MG; | |||
| Crystal structure of 14-3-3 sigma in complex with 13mer Amot-p130 peptide and fragment 22 |
Heteromer P31947; Q4VCS5; | 100.0 | 2×K92; 2×CL; | |||
| Crystal structure of human 14-3-3 sigma C38V/N166H in complex with TASK-3 peptide and stabilizer FC… |
Heteromer P31947; Q9NPC2; | 99.13 | 2×FC7; 2×CL; 6×MG; | |||
| Crystal structure of human 14-3-3 sigma C38N/N166H in complex with task-3 peptide and stabilizer Fu… |
Heteromer P31947; Q9NPC2; | 99.13 | 2×FJA; 6×MG; 2×CL; | |||
| Crystal structure of human 14-3-3 sigma C38N/N166H in complex with task-3 peptide and stabilizer Fu… |
Heteromer P31947; Q9NPC2; | 99.13 | 2×FC7; 4×MG; 4×CA; 4×CL; | |||
| Small molecule stabilizer for 14-3-3/ChREBP (Cmd 43) |
Heteromer P31947; Q9NP71; | 100 | 6×MG; 2×UH9; | |||
| Crystal structure of 14-3-3 sigma in complex with NPM1 phosphopeptide and stabilizer Fusicoccin-A |
Heteromer P06748; P31947; | 100 | 2×FSC; 2×CL; | |||
| Structure of 14-3-3 sigma in complex with PADI6 14-3-3 binding motif I |
Heteromer P31947; Q6TGC4; | 100.0 | ||||
| Fragment AZ-004 binding at the TAZpS89/14-3-3 sigma interface |
Heteromer P31947; Q9GZV5; | 100.0 | 4×L1T; | |||
| Fragment AZ-019 binding at the p53pT387/14-3-3 sigma interface |
Heteromer P04637; P31947; | 100.0 | 2×MG; 2×CL; 2×GOL; 2×KDK; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-045 |
Heteromer P31947; Q04206; | 100.0 | 4×CL; 2×V1H; 2×MG; | |||
| Crystal structure of C-terminal modified Tau peptide-hybrid 3.2e with 14-3-3sigma |
Heteromer P10636; P31947; | 100.0 | 2×CA; 2×CL; 2×NA; 2×60H; | |||
| Structure of 14-3-3 isoform sigma in complex with a C-Raf1 peptide and a stabilizing small molecule… |
Heteromer P04049; P31947; | 100.0 | 2×M1T; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-178 |
Heteromer P31947; Q04206; | 100.0 | 4×CL; 2×V4K; 2×CA; 2×GOL; | |||
| Crystal structure of 14-3-3 sigma in complex with Phosphorylated and Farnesylated Rnd3 peptide and … |
Heteromer P31947; P61587; | 100 | 2×FSC; 4×MG; 2×CL; 2×FAR; | |||
| SARS-CoV-2 Nucleocapsid phosphopeptide 193-200 bound to human 14-3-3 sigma |
Heteromer P0DTC9; P31947; | 100.0 | 4×PEG; 2×GOL; 4×BR; 1×TRS; | |||
| 14-3-3 protein interaction with Estrogen Receptor Alpha provides a novel drug target interface |
Heteromer P03372; P31947; | 100 | 6×MG; | |||
| 14-3-3 sigma with RelA/p65 binding site pS45 and covalently bound TCF521-027 |
Heteromer P31947; Q04206; | 100 | 2×CL; 2×L3V; 2×CA; 2×MG; | |||
| Small molecule stabilizer for 14-3-3/ChREBP (Cmd 42) |
Heteromer P31947; Q9NP71; | 100 | 6×MG; 2×XSL; | |||
| 14-3-3 protein interaction with Estrogen Receptor Alpha provides a novel drug target interface |
Heteromer P03372; P31947; | 100 | 2×FSC; | |||
| Crystal structure of 14-3-3 sigma in complex with SSBP4 phosphopeptide and stabilizer Fusicoccin-A |
Heteromer P31947; Q9BWG4; | 100.0 | 2×FSC; 2×CL; 4×MG; | |||
| Crystal structure of human 14-3-3 sigma C38V/N166H in complex with TASK-3 peptide and stabilizer Co… |
Heteromer P31947; Q9NPC2; | 99.09 | 2×CW7; 2×MG; | |||
| 14-3-3 sigma in complex with hDMX-342+367 peptide |
Heteromer O15151; P31947; | 100.0 | 1×B3P; | |||
| 14-3-3 sigma in complex with hDMX-367 peptide |
Heteromer O15151; P31947; | 100.0 | 1×SO4; | |||
| Henipavirus W protein interacts with 14-3-3 to modulate host gene expression |
Heteromer P0C1C7; P31947; | 100 | 2×CA; | |||
| Structure of 14-3-3 sigma delta C with electrophilic peptide 3MHR-5 |
Heteromer P31947; P46937; | 100.0 | 2×TJI; 2×MG; 6×CL; | |||
| Crystal structure of 14-3-3 sigma in complex with 13mer Amot-p130 peptide and fragment 12 |
Heteromer P31947; Q4VCS5; | 100.0 | 2×K7Q; 4×CA; 6×CL; 2×MG; | |||
| 14-3-3 sigma in complex with FOXO1 pT24 peptide |
Heteromer P31947; Q12778; | 100.0 | 1×B3P; 2×GOL; | |||
| Crystal structure of 14-3-3 sigma in complex with RIPK2 phosphopeptide and stabilizer Fusicoccin-A |
Heteromer O43353; P31947; | 100.0 | 2×FSC; 4×MG; 2×CL; | |||
| Crystal structure of 14-3-3 sigma in complex with a C-terminal Estrogen Receptor alpha phosphopepti… |
Heteromer P03372; P31947; | 100.0 | 2×MG; 2×PJN; | |||
| Ternary complex of 14-3-3 sigma, p27pT198 phosphopeptide, and WQ176 |
Heteromer P31947; P46527; | 100.0 | 2×0HP; 4×MG; 2×CL; | |||
| Human 14-3-3 sigma CLU3 mutant complexed with short HSPB6 phosphopeptide |
Heteromer O14558; P31947; | 99.56 | 2×TRS; | |||
| Crystal structure of an Estrogen Receptor alpha 8-mer phosphopeptide in complex with 14-3-3sigma st… |
Heteromer P03372; P31947; | 100.0 | 2×NJW; | |||
| Engineered conjugation of lysine-specific molecular tweezers with ExoS derived peptidic inhibitor e… |
Heteromer G3XDA1; P31947; | 100.0 | 1×TWZ; 3×NA; 1×GOL; | |||
| Crystal structure of 14-3-3 sigma in complex with a C-terminal Estrogen Receptoralpha phosphopeptid… |
Heteromer P03372; P31947; | 100.0 | 2×MG; 2×8CQ; | |||
| 14-3-3 Sigma in complex with phosphorylated Gab2pT391 peptide - 96h incubation |
Heteromer P31947; Q9UQC2; | 100.0 | 4×MG; | |||
| 14-3-3 Sigma in complex with phosphorylated Gab2pT391 peptide - 48h incubation |
Heteromer P31947; Q9UQC2; | 100 | 4×MG; | |||
| 14-3-3 Sigma in complex with phosphorylated Gab2pT391 peptide - 24h incubation |
Heteromer P31947; Q9UQC2; | 100 | 4×MG; | |||
| 14-3-3 Sigma in complex with phosphorylated Gab2pT391 peptide - 1h incubation |
Heteromer P31947; Q9UQC2; | 100.0 | 4×MG; | |||
| Human 14-3-3 sigma fused to the StARD1 peptide including phosphoserine-195 |
Heteromer P31947; P49675; | 98.7 | ||||
| SARS-CoV-2 Nucleocapsid phosphopeptide 201-210 bound to human 14-3-3 sigma |
Heteromer P0DTC9; P31947; | 98.67 | 3×CL; | |||
| Human 14-3-3 sigma fused to the AANAT peptide including phosphoserine-205 |
Heteromer P31947; Q16613; | 99.13 | ||||
| CH2 chimera of human 14-3-3 sigma with the Gli1 phosphopeptide around Ser640 |
Heteromer P08151; P31947; | 99.56 | 4×SO4; 2×TRS; | |||
| CH3 chimera of human 14-3-3 sigma with the StARD1 peptide including Ser57 |
Heteromer P31947; P49675; | 100.0 | 1×TRS; 1×SO4; | |||
| Complex of human 14-3-3 sigma CLU1 mutant with phosphorylated heat shock protein B6 |
Heteromer O14558; P31947; | 98.67 | 2×TRS; 1×NI; | |||
| GBP1 bound by 14-3-3sigma |
Heteromer P31947; P32455; | 100.0 | ||||
| CryoEM structure of activated CRAF/MEK/14-3-3 complex with NST-628 |
Heteromer P04049; P31947; Q02750; | 100.0 | 2×A1AHE; | |||
| Human 14-3-3 sigma complexed with long HSPB6 phosphopeptide |
Heteromer O14558; P31947; | 100 | ||||
| CH1 chimera of human 14-3-3 sigma with the HSPB6 phosphopeptide in a conformation with swapped phos… | homo-4-mer | 100.0 | 5×PEG; | |||
| The crystal structure of 14-3-3-sigma at 2.8 angstrom resolution | homo-2-mer | 100.0 | ||||
| Ternary complex of Estrogen Receptor alpha peptide and 14-3-3 sigma C42 mutant bound to disulfide f… | homo-2-mer | 99.13 | 2×MG; 2×GEH; | |||
| Crystal structure of 14-3-3sigma and a p53 C-terminal 12-mer synthetic phosphopeptide stabilized by… | homo-2-mer | 100.0 | 2×FSC; 2×CL; 2×MG; | |||
| 14-3-3sigma in complex with SHN3pS542 phosphopeptide crystal structure | homo-2-mer | 100 | 8×MG; | |||
| Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screening | homo-2-mer | 100.0 | 10×MG; 4×CL; 2×GOL; 2×Y04; | |||
| Ternary structure of 14-3-3s, ERRg phosphopeptide and dual-reactive compound 10 | homo-2-mer | 99.57 | 4×MG; 2×CL; 2×OQ3; | |||
| Ternary structure of 14-3-3s, ERRg phosphopeptide and dual-reactive compound 4 | homo-2-mer | 99.57 | 6×MG; 2×CL; 2×OQ9; | |||
| Ternary structure of 14-3-3sigma, strep-tagged PKA-responsive ERa phosphopeptide, and Fusicoccin-A. | homo-2-mer | 100.0 | 6×MG; 2×SIT; | |||
| 14-3-3sigma bound to strep-tagged PKA-responsive ERa phosphopeptide | homo-2-mer | 100 | 8×MG; | |||
| 14-3-3sigma bound to PKA-responsive ERa phosphopeptide | homo-2-mer | 100 | 8×MG; | |||
| 14-3-3 Sigma in complex with phosphorylated ATPase peptide | homo-2-mer | 100 | 6×MG; 2×CA; | |||
| 14-3-3sigma in complex with SHN3pT869 phosphopeptide crystal structure | homo-2-mer | 100 | 8×MG; | |||
| Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screening | homo-2-mer | 100.0 | 2×1CT; 4×GOL; 6×CL; 4×MG; | |||
| 14-3-3s binding to non-natural peptide 2d | homo-2-mer | 100 | 4×MG; | |||
| Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screening | homo-2-mer | 100.0 | 2×2CT; 4×GOL; 4×CL; 6×MG; | |||
| Crystal structure of 14-3-3sigma in complex with a RapGef2 pT740 phosphopeptide inhibited by semi-s… | homo-2-mer | 100.0 | 2×HY5; 2×TPO; 2×CL; 4×NA; | |||
| Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screening | homo-2-mer | 100.0 | 10×MG; 4×CL; 2×GOL; 2×0KH; | |||
| Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screening | homo-2-mer | 100.0 | 6×MG; 6×CL; 2×GOL; 2×0KB; | |||
| Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screening | homo-2-mer | 100.0 | 8×MG; 4×CL; 2×GOL; 2×Y09; | |||
| Ternary complex of Estrogen Receptor alpha peptide and 14-3-3 sigma C42 mutant bound to disulfide f… | homo-2-mer | 99.13 | 4×MG; 2×GF8; | |||
| Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screening | homo-2-mer | 100.0 | 6×MG; 4×CL; 2×GOL; 2×Y03; | |||
| Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screening | homo-2-mer | 100.0 | 10×MG; 4×CL; 2×GOL; 2×Y06; | |||
| Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screening | homo-2-mer | 100.0 | 10×MG; 4×CL; 2×GOL; 2×Y07; | |||
| Small-molecule inhibitor of 14-3-3 protein-protein interactions | homo-2-mer | 100 | 6×MG; 2×OO8; | |||
| Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screening | homo-2-mer | 100.0 | 4×MG; 4×CL; 2×GOL; 2×0KG; | |||
| Small-molecule inhibitors of 14-3-3 protein-protein interactions from virtual screening | homo-2-mer | 100.0 | 6×MG; 4×CL; 2×GOL; 2×0KC; | |||
| Covalent attachment of pyridoxal-phosphate derivatives to 14-3-3 proteins | homo-2-mer | 100.0 | 4×MG; 6×CL; 2×GOL; | |||
| 14-3-3s binding to non-natural peptide 2c | homo-2-mer | 100 | 4×MG; | |||
| Crystal structure of 14-3-3 sigma in complex with CIP2ApS904 peptide | homo-2-mer | 100 | 2×CL; 4×MG; | |||
| Binary complex of 14-3-3 sigma and a high-affinity non-canonical 9-mer peptide binder | homo-2-mer | 100 | 8×MG; 2×CL; | |||
| Crystal structure of 14-3-3 sigma in complex with CIP2ApS904 peptide and stabilizing Fusicoccin A | homo-2-mer | 100.0 | 2×FSC; 8×MG; 4×CL; | |||
| Human 14-3-3 sigma fused to the StARD1 peptide including phosphoserine-57 | homo-2-mer | 99.56 | 3×PGE; 1×IMD; | |||
| 14-3-3 in complex with Pyrin pS208 | homo-2-mer | 100.0 | 8×MG; | |||
| Structure of 14-3-3 sigma delta C with electrophilic peptide 4IEA-5 | homo-2-mer | 100.0 | 2×TJI; 2×MG; 6×CL; | |||
| Molecular tweezers modulate 14-3-3 protein-protein interactions. | homo-2-mer | 100.0 | 2×9SZ; 2×CL; 2×GOL; | |||
| Ligand-free state of human 14-3-3 sigma isoform | homo-2-mer | 100.0 | 2×PEG; 12×SO4; | |||
| Crystal structure of the human sigma isoform of 14-3-3 in complex with a mode-1 phosphopeptide | homo-2-mer | 100.0 | 1×CA; | |||
| 14-3-3 sigma complexed with a phosphorylated 16E6 peptide | homo-2-mer | 98.7 | 2×TAR; | |||
| human 14-3-3 sigma isoform in complex with IMP | homo-2-mer | 100.0 | 2×IMP; 2×SO4; | |||
| Human 14-3-3 sigma isoform in complex with PLP | homo-2-mer | 100.0 | 1×PLP; 2×SO4; | |||
| Molecular tweezers modulate 14-3-3 protein-protein interactions | homo-2-mer | 100.0 | 2×9SZ; 2×CL; | |||
| CH1 chimera of human 14-3-3 sigma with the HSPB6 phosphopeptide in a conformation with self-bound p… | homo-2-mer | 99.55 | 11×CD; | |||
1 SWISS-MODEL model
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 3cu8.1.A | homo-2-mer | 0.83 | 1×ARG; 1×ARG; 1×MG; 1×PPI; | 69.67 | ||